Sunday , June 25 2017
Home / Von Willebrand Disease

Von Willebrand Disease

Baxalta Wins FDA Approval for Vonvendi for Treatment of Patients with Von Willebrand Disease

BANNOCKBURN, Ill.–(BUSINESS WIRE)– Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (Recombinant)]. VONVENDI is the first and only recombinant treatment for …

Read More »

CSL Behring Marks World Hemophilia Day by with Significant Contributions to the World Federation of Hemophilia

In recognition of World Hemophilia Day, held on April 17, CSL Behring announced that it is donating ten million international units (IUs) of bleeding disorder protein therapies and contributing a significant financial contribution to the World Federation of Hemophilia (WFH). CSL Behring said that it has once again committed to …

Read More »